Depression drug trial halted early: what we know
NCT ID NCT04249596
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug tianeptine in 38 adults with major depression that did not improve after at least two other treatments. Participants took tianeptine three times a day for 8 weeks. The goal was to see if it reduced depression symptoms and changed how the brain processes emotional and physical pain. However, the trial was terminated early, so the results are incomplete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-RESISTANT DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
New York State Psychiatric Institute
New York, New York, 10032, United States
-
Stanford Depression Research Clinic at Stanford University School of Medicine
Stanford, California, 94305, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tianeptine (a drug that may affect mood and pain signaling)
What this could lead to
If it had succeeded, this could have pointed toward a new option for people with depression that hasn't responded to other treatments.
What could go wrong
The trial was terminated early, so we don't have clear results. It was also a small study (38 participants) and only tested one dose for 8 weeks, so any findings would be very preliminary.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.